Clinical Trials
3 trialsNCT07467330 2026-03-12
Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
Fujian Cancer Hospital
Phase 3 Recruiting
NCT07207070 2025-12-30
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 3 Recruiting
NCT06612814 2024-09-25
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Fudan University
Phase 3 Active not recruiting